A new clinical trial will determine whether a third dose of the vaccine for people with weakened immune systems gives a stronger immune response than two doses.
A new clinical trial to determine whether a third dose of the vaccine will improve the immune response of people with weakened immune systems has been launched in the UK.
The study, OCTAVE DUO, will offer immunocompromised or immunocompromised people a Pfizer, Moderna or Novavax vaccine to determine if it will give an immune response stronger than two doses.
The £ 2.2million study will build on the OCTAVE trial, led by the University of Glasgow and coordinated by the Cancer Research UK Clinical Trials Unit at the University of Birmingham.
Health and Social Affairs Secretary Sajid Javid said: ‘Vaccines have built a strong wall of defense in the UK and it allows most of us to learn how to live safely with COVID -19.
“We know that some people may be less protected by the vaccine than others, so we are planning a booster program in the fall, prioritizing those most at risk.
“This new study will play an important role in helping to shape the deployment of future vaccine doses for these specific risk groups,” he added.
The OCTAVE trial published preliminary data showing that 89 percent of immunocompromised or immunocompromised people generate antibodies after vaccination, and 60 percent generate a strong antibody response after two doses of a vaccine.
However, 40 percent of people in these groups exhibited a weak or undetectable immune response after two doses, and the level of antibody response varied between the groups studied.
Thank you for taking the time to read this article, be sure to come back to the Euro Weekly News website for all your up-to-date local and international news and follow us on Facebook and Instagram.